SCRS Welcomes Roche as a New Global Impact Partner
Ellicott City, MD – SCRS announced today that Roche has become a Global Impact Partner (GIP), making this the 40th partner for SCRS in just the third year of the GIP program. Through this partnership, Roche brings their leadership as the world’s largest biotechnology company. As a GIP, Roche will serve on the SCRS Global Impact Board and work closely with the organization’s Leadership Council on setting and working toward strategic initiatives.
“Roche has demonstrated accomplishment in the field of clinical trials and personalized medicine and we look forward to their participation in our mission of supporting sites,” said SCRS President, Christine Pierre. “The success of the GIP program indicates that the industry understands the importance of site sustainability and wants to take action.”
“Roche is thrilled to be joining SCRS as a Global Impact Partner,” said Virginia Nido, Global Head of Industry Collaborations Management at Roche. “We look forward to exploring collaborative and innovative initiatives with SCRS that will streamline and increase the quality of clinical trials, and importantly, reduce the administrative burden on clinical sites. With the expanding global footprint of SCRS, we at Roche look forward to building strong site/sponsor relationships across the world.”
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 4,000 research sites in 54 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. For more information, please visit www.roche.com.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
